Life Biosciences

Overview
News
Longevity Tech?
Product stageSegments
Seed
?
Longevity-focused cell and gene therapy
?

Life Biosciences is a biotech company that develops therapeutics seeking to prevent, treat, and reverse various aging-related diseases. The company targets two biological mechanisms contributing to aging: Epigenetic alterations and loss of proteostasis. Its Epigenetic Reprogramming Platform focuses on therapies inducing the expression of three Yamanaka factors (OCT4, SOX2, and KLF4 [OSK]) to reprogram the epigenome. The company claims that this has demonstrated safety and efficacy in preclinical nerve crush and glaucoma models and, as of October 2023, this was at the preclinical stage.

In addition, Life Biosciences' Chaperone-Mediated Autophagy Platform focuses on small molecule activators of chaperone-mediated autophagy that reduce the aggregated protein accumulation. This is claimed to have demonstrated safety and efficacy in preclinical models of neurodegeneration and retinal degeneration. As of October 2023, this was at the discovery stage.

In October 2018, Life Biosciences acquired Lua, the communication and technology platform to utilize its technology in the development of Life Bioscience’s platforms. Lua is a web and mobile-based technology platform focused on enhancing patient outcomes by facilitating communication between providers and patients. 

Key customers and partnerships

In May 2023, Life Biosciences entered a manufacturing partnership with Ohio-based gene therapy development company Forge Biologics to help advance its epigenetic reprogramming platform. Through this partnership, Forge Biologics is expected to provide adeno-associated virus (AAV) process development, toxicology, current good manufacturing practices, and analytical services to Life Biosciences. Life Biosciences will utilize Forge’s platform processes, such as HEK293 suspension ignition cell and pEMBR adenovirus helper plasmid.

Funding and financials

In January 2022, Life Biosciences raised USD 82 million in a Series C funding round led by Alpha Wave Ventures. The company expected to use the funds to accelerate R&D efforts toward the company’s platforms.

HQ location:
75 Park Plaza Level Three Boston MA USA
Founded year:
2017
Employees:
11-50
IPO status:
Private
Total funding:
USD 206.8 mn
Last Funding:
USD 82.0 mn (Series C; Jan 2022)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.